GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Beneish M-Score

AngioDynamics (AngioDynamics) Beneish M-Score : -2.88 (As of Apr. 25, 2024)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.88 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for AngioDynamics's Beneish M-Score or its related term are showing as below:

ANGO' s Beneish M-Score Range Over the Past 10 Years
Min: -3.08   Med: -2.61   Max: -1.98
Current: -2.88

During the past 13 years, the highest Beneish M-Score of AngioDynamics was -1.98. The lowest was -3.08. And the median was -2.61.


AngioDynamics Beneish M-Score Historical Data

The historical data trend for AngioDynamics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Beneish M-Score Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.37 -2.48 -2.61 -2.21 -2.86

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.64 -2.86 -2.54 -2.70 -2.88

Competitive Comparison of AngioDynamics's Beneish M-Score

For the Medical Instruments & Supplies subindustry, AngioDynamics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Beneish M-Score falls into.



AngioDynamics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of AngioDynamics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0042+0.528 * 1.0384+0.404 * 0.4406+0.892 * 0.9681+0.115 * 0.9317
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0316+4.679 * -0.018843-0.327 * 1.2015
=-2.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb24) TTM:Last Year (Feb23) TTM:
Total Receivables was $49.5 Mil.
Revenue was 75.182 + 79.073 + 78.679 + 91.074 = $324.0 Mil.
Gross Profit was 35.861 + 40.262 + 40.06 + 46.359 = $162.5 Mil.
Total Current Assets was $196.9 Mil.
Total Assets was $324.8 Mil.
Property, Plant and Equipment(Net PPE) was $37.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $28.5 Mil.
Selling, General, & Admin. Expense(SGA) was $145.5 Mil.
Total Current Liabilities was $85.9 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Net Income was -187.736 + -29.048 + 45.884 + -21.467 = $-192.4 Mil.
Non Operating Income was -188.536 + -6.441 + 44.472 + -18.536 = $-169.0 Mil.
Cash Flow from Operations was -12.526 + 5.266 + -25.899 + 15.954 = $-17.2 Mil.
Total Receivables was $50.9 Mil.
Revenue was 80.712 + 85.429 + 81.537 + 86.998 = $334.7 Mil.
Gross Profit was 40.504 + 45.078 + 42.305 + 46.455 = $174.3 Mil.
Total Current Assets was $152.6 Mil.
Total Assets was $542.8 Mil.
Property, Plant and Equipment(Net PPE) was $45.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $31.0 Mil.
Selling, General, & Admin. Expense(SGA) was $145.7 Mil.
Total Current Liabilities was $69.6 Mil.
Long-Term Debt & Capital Lease Obligation was $49.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(49.475 / 324.008) / (50.892 / 334.676)
=0.152697 / 0.152063
=1.0042

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(174.342 / 334.676) / (162.542 / 324.008)
=0.520928 / 0.50166
=1.0384

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (196.907 + 37.04) / 324.842) / (1 - (152.574 + 45.559) / 542.849)
=0.279813 / 0.635013
=0.4406

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=324.008 / 334.676
=0.9681

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(30.983 / (30.983 + 45.559)) / (28.452 / (28.452 + 37.04))
=0.404784 / 0.434435
=0.9317

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(145.481 / 324.008) / (145.667 / 334.676)
=0.449004 / 0.435248
=1.0316

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 85.874) / 324.842) / ((49.807 + 69.632) / 542.849)
=0.264356 / 0.220023
=1.2015

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-192.367 - -169.041 - -17.205) / 324.842
=-0.018843

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

AngioDynamics has a M-score of -2.88 suggests that the company is unlikely to be a manipulator.


AngioDynamics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421